Vericel (NASDAQ:VCEL) Insider Jonathan Mark Hopper Sells 3,472 Shares of Stock

Vericel Corporation (NASDAQ:VCEL) insider Jonathan Mark Hopper sold 3,472 shares of Vericel stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $35.00, for a total transaction of $121,520.00. Following the completion of the sale, the insider owned 75,556 shares in the company, valued at $2,644,460. The trade was a 4.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vericel Trading Down 0.2%

Shares of VCEL stock opened at $34.08 on Tuesday. The firm has a market capitalization of $1.74 billion, a P/E ratio of 109.94 and a beta of 1.20. Vericel Corporation has a 1 year low of $28.95 and a 1 year high of $45.97. The firm’s fifty day moving average price is $34.60 and its two-hundred day moving average price is $35.83.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings results on Thursday, February 26th. The biotechnology company reported $0.45 earnings per share for the quarter, hitting the consensus estimate of $0.45. The firm had revenue of $92.92 million for the quarter, compared to analyst estimates of $92.66 million. Vericel had a return on equity of 5.17% and a net margin of 5.98%.The business’s quarterly revenue was up 23.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.38 EPS. As a group, equities research analysts forecast that Vericel Corporation will post 0.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in VCEL. Huntington National Bank increased its holdings in shares of Vericel by 51.3% during the 3rd quarter. Huntington National Bank now owns 805 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 273 shares during the last quarter. Kestra Advisory Services LLC acquired a new position in Vericel in the 4th quarter valued at about $27,000. Abich Financial Wealth Management LLC acquired a new position in Vericel in the 3rd quarter valued at about $31,000. Quarry LP acquired a new position in Vericel in the 4th quarter valued at about $31,000. Finally, Farther Finance Advisors LLC grew its stake in Vericel by 116.5% in the 4th quarter. Farther Finance Advisors LLC now owns 970 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 522 shares during the last quarter.

Analyst Ratings Changes

Several research analysts have recently weighed in on VCEL shares. Truist Financial lowered their price objective on shares of Vericel from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Thursday, December 18th. HC Wainwright boosted their price objective on shares of Vericel from $60.00 to $64.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Wall Street Zen upgraded shares of Vericel from a “hold” rating to a “buy” rating in a research note on Saturday, March 28th. Leerink Partners restated an “outperform” rating and set a $46.00 price objective on shares of Vericel in a research note on Tuesday, March 10th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Vericel in a research note on Monday, December 29th. Five analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Vericel has a consensus rating of “Moderate Buy” and an average price target of $56.00.

About Vericel

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.